As early and effective antiretroviral therapy has become more widespread, HIV has
transitioned from a progressive, fatal disease to a chronic, manageable disease marked by …

Although the extensive rollout of antiretroviral (ARV) therapy resulted in a longer life
expectancy for people living with human immunodeficiency virus (PLHIV), such individuals …

Background In human immunodeficiency virus (HIV) treatment, tenofovir alafenamide (TAF)
is associated with greater increases in all fasting cholesterol subgroups compared with …

Purpose In 1998, the AIDS Therapy Evaluation in the Netherlands (ATHENA) national
observational HIV cohort was established to demonstrate the lifesaving effectiveness of …

Background Both immediate and deferred switching from a ritonavir-boosted protease
inhibitor (PI/r)–based regimen to a dolutegravir (DTG)–based regimen may improve lipid …

Current biomarkers to assess the risk of complications of both acute and chronic viral
infection are suboptimal. Prevalent viral infections like human immunodeficiency virus (HIV) …

Background: People living with HIV (PLWH) experience a higher cardiovascular disease
(CVD) risk. Yet, traditional algorithms are often used to estimate CVD risk. We evaluated the …

Our understanding of mechanisms of elevated ASCVD risk in HIV continues to evolve, and
the optimal treatment for CVD in HIV aside from targeting traditional risk factors remains …

People living with HIV have higher risks of cardiovascular disease (CVD) including
myocardial infarction, 1, 2 heart failure, 3, 4 stroke, 5 pulmonary hypertension, 6 and sudden …

Cardiovascular disease, venous thrombosis, and microvascular disease in people with HIV
(PWH) is predicted to increase in an aging HIV-infected population. Endothelial damage and …